New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes
Novartis has announced results of a new post-hoc analysis in a subgroup of patients with reduced ejection fraction heart failure (HFrEF) and diabetes suggesting that Entresto® (sacubitril/valsartan) tablets improved glycemic control, as assessed by hemoglobin A1c (HbA1c) testing, compared to ACE-inhibitor enalapril[1].
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news
More News: Cardiology | Diabetes | Diovan | Enalapril | Endocrinology | Heart | Heart Failure | Pharmaceuticals